IP Verse

Vertex Pharmaceuticals competitive analysis

Latest publications and patents of Vertex Pharmaceuticals New

Explore the latest publications and patents granted to Vertex Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Sep 24, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Vertex Pharmaceuticals

EP4069691
Sep 18, 2024Substituted Tetrahydrofurans As Modulators Of Sodium ChannelsGranted And Under Opposition
EP2464337
Jun 26, 2024Pharmaceutical Composition And Administrations ThereofPatent Maintained As Amended
EP2914248
Oct 18, 2023Pharmaceutical Compositions For The Treatment Of Cftr Mediated DiseasesPatent Maintained As Amended
EP3352757
Aug 16, 2023Administration Of Deuterated Cftr PotentiatorsGranted And Under Opposition
EP3925607
Jun 28, 2023Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated DiseasesGranted And Under Opposition
EP3880197
Feb 22, 2023Methods Of Treatment For Cystic FibrosisGranted And Under Opposition
EP3752510
Dec 7, 2022Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making ThemGranted And Under Opposition
EP3798214
Sep 14, 2022Modulators Of Cystic Fibrosis Transmembrane Conductance RegulatorGranted And Under Opposition
EP3345625
Dec 9, 2020Pharmaceutical Composition And Administrations ThereofGranted And Under Opposition
EP3203840
Aug 5, 2020Modulators Of Cystic Fibrosis Transmembrane Conductance RegulatorGranted And Under Opposition

Latest patents of Vertex Pharmaceuticals opposed by its competitors

Explore Vertex Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4069691
Sep 18, 2024Substituted Tetrahydrofurans As Modulators Of Sodium Channels1
EP2464337
Jun 26, 2024Pharmaceutical Composition And Administrations Thereof1
EP2914248
Oct 18, 2023Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases1
EP3352757
Aug 16, 2023Administration Of Deuterated Cftr Potentiators1
EP3925607
Jun 28, 2023Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases1
EP3880197
Feb 22, 2023Methods Of Treatment For Cystic Fibrosis2
EP3752510
Dec 7, 2022Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making Them1
EP3798214
Sep 14, 2022Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1
EP3345625
Dec 9, 2020Pharmaceutical Composition And Administrations Thereof3
EP3203840
Aug 5, 2020Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1

Latest PTAB cases involving Vertex Pharmaceuticals

Discover the latest PTAB cases involving Vertex Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 30, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Vertex Pharmaceuticals

IPR2016-00558Feb 3, 2016LUPINVERTEX PHARMACEUTICALS INCORPORATEDFinal Written Decision
IPR2015-00405Dec 10, 2014LUPINVERTEX PHARMACEUTICALS INCORPORATEDTerminated-Settled
IPR2013-00024Oct 18, 2012RANBAXY LABORATORIESVERTEX PHARMACEUTICALS INCORPORATEDTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Vertex Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
VERTEX PHARMACEUTICALS INCORPORATED - 13 - 3Non-Active
GENERICS UK211 - - - Highly Aggressive
LUPIN - 115 - Highly Aggressive
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive